Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 1.00 |
| ▸ | ICMT | O60725 | 10/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12542194 | 1.00 | OPRM1 (1.00) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL19937128 | 0.92 | OPRM1 (0.84) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL12541297 | 0.92 | OPRM1 (0.84) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL19614667 | 0.90 | OPRM1 (0.82) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL12541950 | 0.90 | OPRM1 (0.81) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL12697585 | 0.89 | OPRM1 (0.80) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL19936875 | 0.88 | HTR1A (0.82) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL12541340 | 0.87 | OPRM1 (0.77) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL18886950 | 0.87 | OPRM1 (1.00) | OPRM1ICMTHTR1AHTR7HTR6 | |
| SCHEMBL18886938 | 0.86 | OPRM1 (0.75) | OPRM1ICMTHTR1AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688403-B1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, ATRIP, CHEK1 | OPRM1 4802/4885ICMT 2306/4885HTR1A 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.